The role and efficacy of Fruquintinib

Fruquintinib (Fruquintinib) is an oral small molecule targeted therapy drug that is a multicaseokinase inhibitor. Its main function is to block the angiogenesis process of tumors by inhibiting vascular endothelial growth factor receptors (VEGFR), especially VEGFR-1, VEGFR-2 and VEGFR-3. This makes fruquintinib an anti-angiogenic drug for the treatment of solid tumors such as advanced gastric cancer and colorectal cancer.

1. Inhibition of angiogenesis: Fruquintinib mainly inhibits the activity of VEGFR, especially VEGFR-2, thereby blocking the tumor's demand for new blood vessels. Angiogenesis plays a key role in tumor growth and spread, as tumor cells require new blood vessels to supply oxygen and nutrients. The anti-angiogenic effects of fruquintinib can reduce the blood supply to tumors, thereby limiting tumor growth and spread.

2. Inhibition of tumor growth: Fruquintinib affects angiogenesis by inhibitingVEGFR, thus inhibiting tumor growth. This mechanism makes fruquintinib an effective anti-cancer drug, especially in some patients with advanced gastric cancer and colorectal cancer, when other treatments are ineffective or unsuitable, making fruquintinib a viable treatment option.

3. Improve survival rate and prolong survival: Clinical studies have shown that fruquintinib has achieved significant efficacy in the treatment of advanced colorectal cancer and gastric cancer. After patients receive fruquintinib treatment, tumor shrinkage and disease improvement can usually be observed, thereby improving the patient's survival rate and prolonging their survival.

4. Reducing cancer-related symptoms: In addition to directly inhibiting tumor growth, fruquintinib may also improve patients' quality of life by reducing cancer-related symptoms, such as pain, fatigue, etc.

5. Combined application with other treatment methods: In some cases, fruquintinib can also be used in combination with other anti-cancer treatments (such as chemotherapy, radiotherapy, etc.) to achieve better therapeutic effects. This comprehensive treatment strategy can be individually designed by doctors according to the patient's specific conditions.

Although fruquintinib has shown certain efficacy in cancer treatment, it also has some potential side effects and limitations. Common adverse reactions include hypertension, hand-foot syndrome, proteinuria, etc. Therefore, when using fruquintinib, physicians need to carefully evaluate the patient's physical condition, monitor the patient's response, and make dose adjustments or discontinuation as needed.

In summary, fruquintinib, as a targeted therapy, has shown significant potential in the treatment of cancers such as advanced colorectal cancer and gastric cancer. However, treatment options should be individualized for each patient and tailored to the patient's specific circumstances and medical history to maximize treatment effectiveness and reduce potential side effects. Future research and clinical practice will further reveal the mechanism of action and application prospects of fruquintinib in cancer treatment.

Fruquintinib is a drug developed in Hong Kong, China. It has been approved for marketing by the State Food and Drug Administration and has been included in medical insurance. Patients can buy it in domestic hospital pharmacies at a price of about one to two thousand. For specific prices, please consult the local hospital pharmacy.